Title:
ベータ７インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
Document Type and Number:
Japanese Patent JP6740294
Kind Code:
B2
Abstract:
Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator ("biomarker") of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of assessing the effect, efficacy, or responsiveness to beta7 integrin antagonist treatment by measuring gene expression levels of one or more integrin receptor ligands, lymphocyte genes, cytokine genes, or the number of alphaE-positive cells in intestinal crypt epithelium are provided.
More Like This:
Inventors:
Deal, lauri
Kia, mary
Tan, Meina Tao
Way, Xiao Hoi
Williams, Mana Bee.
Kia, mary
Tan, Meina Tao
Way, Xiao Hoi
Williams, Mana Bee.
Application Number:
JP2018147604A
Publication Date:
August 12, 2020
Filing Date:
August 06, 2018
Export Citation:
Assignee:
Genentech, Incorporated
International Classes:
G01N33/53; C07K14/47; C07K14/705; C07K16/28; C12N15/06; C12N15/13; C12P21/08; C12Q1/06; C12Q1/6813
Domestic Patent References:
| JP2011521236A | ||||
| JP2007531735A |
Foreign References:
| WO2011153501A2 | ||||
| WO2012135589A1 |
Other References:
Paul J Rutgeerts et al.,A randomised phase I study of etrolizumab(rhuMAb β7) in moderate to severe ulcerative colitis,Gut,2012年 6月20日,vol.62,p.1122-1130
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation